What are the side effects of dasatinib and headache?

Dasatinib (Dasatinib) is a tyrosine kinase inhibitor (TKI) widely used in the treatment of chronic myelogenous leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). Although it has achieved remarkable efficacy in clinical application, patients often experience some side effects during use, among which headache is a relatively common reaction.

The mechanism by which dasatinib causes headaches is not fully understood, but it can be analyzed from several aspects. First of all, as a targeted drug, dasatinib's mechanism of action is mainly to prevent the proliferation of tumor cells by inhibiting the activity of BCR-ABL fusion protein. However, this inhibitory effect may not be limited to the tumor cells themselves, but may also affect the function of normal cells, including effects on the nervous system. In particular, after drugs are distributed in the body, they may cause headaches due to interference with nerve conduction pathways.

Secondly, the use of dasatinib may cause changes in electrolyte balance in patients. For example, some patients may develop hyponatremia or other electrolyte abnormalities while taking dasatinib, and these changes may increase the risk of headache. Electrolyte imbalances can affect the excitability of nerve cells, causing a variety of neurological symptoms, including headaches.

In addition, the side effects of dasatinib also include digestive system reactions, such as nausea and vomiting, which may indirectly cause headaches. When patients feel physical discomfort, they are often prone to tension and anxiety. This psychological state may also aggravate the feeling of headache. Therefore, if patients can maintain a good mental state during treatment and take effective coping measures, such as relaxation training or psychological counseling, it may help to reduce the occurrence of headaches.